tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksFDA CalendarMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
FDA Calendar
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Private Companies
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Opus Genetics, Inc. (IRD)
NASDAQ:IRD
US Market
IRD
Opus Genetics
RESEARCH TOOLSreports

Opus Genetics (IRD) Stock News & Sentiment

Compare
1,264 Followers
Viatris-Backed Nyxol Trial Completes Phase 3, Setting Up a Key Night-Vision Catalyst
Premium
Company Announcements
Viatris-Backed Nyxol Trial Completes Phase 3, Setting Up a Key Night-Vision Catalyst
9d ago
IRD
VTRS
Ocuphire’s Nyxol Presbyopia Trial Nears Data: What Investors Should Watch
Premium
Company Announcements
Ocuphire’s Nyxol Presbyopia Trial Nears Data: What Investors Should Watch
9d ago
IRD
Buy Rating on Opus Genetics Driven by Advancing Gene Therapy Pipeline, Near‑Term Clinical Catalysts, and Solid Cash Runway
Premium
Ratings
Buy Rating on Opus Genetics Driven by Advancing Gene Therapy Pipeline, Near‑Term Clinical Catalysts, and Solid Cash Runway
10d ago
IRD
Opus Genetics: Advancing Late-Stage Gene Therapy Pipeline and 2026 Data Catalysts Support Buy Rating and $10 Target
Premium
Ratings
Opus Genetics: Advancing Late-Stage Gene Therapy Pipeline and 2026 Data Catalysts Support Buy Rating and $10 Target
10d ago
IRD
Buy Rating on IRD Driven by Low-Risk Presbyopia Launch and High-Potential BEST1 Gene Therapy Pipeline
Premium
Ratings
Buy Rating on IRD Driven by Low-Risk Presbyopia Launch and High-Potential BEST1 Gene Therapy Pipeline
24d ago
IRD
Opus Genetics Closes $25 Million Series B Financing
Premium
Company Announcements
Opus Genetics Closes $25 Million Series B Financing
29d ago
8K
IRD
Opus Genetics: Favorable Risk‑Reward in OPGx-BEST1 Gene Therapy Underpins Buy Rating and $6 Price Target
Premium
Ratings
Opus Genetics: Favorable Risk‑Reward in OPGx-BEST1 Gene Therapy Underpins Buy Rating and $6 Price Target
1M ago
IRD
More IRD News >

IRD News on the Web

Opus Genetics Leadership Quietly Unloads a Wave of Insider Stock
TipRanks News
Neutral
Oppenheimer bullish on Opus Genetics, initiates with an Outperform
TipRanks News
Bullish
Opus Genetics initiated with an Outperform at Oppenheimer
TipRanks News
Bullish
Opus Genetics files to sell 7.37M shares of common stock for holders
TipRanks News
Bullish
Viatris-Backed Nyxol Trial Completes Phase 3, Setting Up a Key Night-Vision Catalyst
TipRanks News
Neutral
Ocuphire’s Nyxol Presbyopia Trial Nears Data: What Investors Should Watch
TipRanks News
Neutral
Opus Genetics price target raised to $10 from $8 at Wedbush
TipRanks News
Bullish
Analysts Offer Insights on Healthcare Companies: AbbVie (ABBV), Pliant Therapeutics (PLRX) and Opus Genetics (IRD)
TipRanks News
Bullish

News Score - Last 7 Days

Neutral
IRD
Sector Average
Media Buzz
This Week3 articles
Weekly Average6.75 articles
News Sentiment
This Week99%
Sector Average67%
See how Bullish or Bearish a stock is based on its recent media coverage.

This score is generated using a formula that combines Media Buzz and News Sentiment.

Media Coverage Analysis

The historical news coverage of this asset in the last three months.

FAQ

What is IRD’s Media Buzz Sentiment?
3 articles about IRD were published this week. In an average week, 6.75 articles are published.
    What is IRD’s weekly average amount of articles?
    In an average week, 6.75 articles about IRD are published.
      What is IRD’s News Sentiment?
      99% of articles about IRD were positive this week, compared to its sector average of 67%.
        Healthcare Stocks that are Trending in the News
        KHTRFKnight Therapeutics
        ABOSAcumen Pharmaceuticals
        KMTSKestra Medical Technologies Ltd.
        OVIDOvid Therapeutics
        MISTMilestone Pharmaceuticals
        Showing the stocks with the most bullish news sentiment over the past week